BR0208771A - Peptìdeo ou poliptìdeo isolados e seus derivados, ácido nucléico codificando o mesmo, vacina copreendendo o mesmo, ácido nucléico codificando o mesmo, vetor compreendendo o referido ácido nucléico, célula hospedeira compreendendo o referido ácido nucléico, composição farmacêutica compreendendo o referido peptìdeo ou polipeptìdeo, método para tratamento ou prevençao de câncer utilizando a referida composição farmacêutica e método para induzir ou magnificar uma resposta imunológica utilizando a referida composição farmacêutica - Google Patents
Peptìdeo ou poliptìdeo isolados e seus derivados, ácido nucléico codificando o mesmo, vacina copreendendo o mesmo, ácido nucléico codificando o mesmo, vetor compreendendo o referido ácido nucléico, célula hospedeira compreendendo o referido ácido nucléico, composição farmacêutica compreendendo o referido peptìdeo ou polipeptìdeo, método para tratamento ou prevençao de câncer utilizando a referida composição farmacêutica e método para induzir ou magnificar uma resposta imunológica utilizando a referida composição farmacêuticaInfo
- Publication number
- BR0208771A BR0208771A BR0208771-5A BR0208771A BR0208771A BR 0208771 A BR0208771 A BR 0208771A BR 0208771 A BR0208771 A BR 0208771A BR 0208771 A BR0208771 A BR 0208771A
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- same
- pharmaceutical composition
- polypeptide
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 14
- 102000039446 nucleic acids Human genes 0.000 title abstract 8
- 108020004707 nucleic acids Proteins 0.000 title abstract 8
- 150000007523 nucleic acids Chemical class 0.000 title abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 6
- 229920001184 polypeptide Polymers 0.000 title abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 230000028993 immune response Effects 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 101100346929 Homo sapiens MUC1 gene Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 102000057860 human MUC1 Human genes 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28013701P | 2001-04-02 | 2001-04-02 | |
| PCT/US2002/010155 WO2002078607A2 (en) | 2001-04-02 | 2002-04-02 | Mucin peptide with immunoenhancing properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0208771A true BR0208771A (pt) | 2004-07-06 |
Family
ID=23071833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0208771-5A BR0208771A (pt) | 2001-04-02 | 2002-04-02 | Peptìdeo ou poliptìdeo isolados e seus derivados, ácido nucléico codificando o mesmo, vacina copreendendo o mesmo, ácido nucléico codificando o mesmo, vetor compreendendo o referido ácido nucléico, célula hospedeira compreendendo o referido ácido nucléico, composição farmacêutica compreendendo o referido peptìdeo ou polipeptìdeo, método para tratamento ou prevençao de câncer utilizando a referida composição farmacêutica e método para induzir ou magnificar uma resposta imunológica utilizando a referida composição farmacêutica |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7285282B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1372691B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP4223813B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20030092044A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1525864A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE376836T1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0208771A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2443045A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60223232T2 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ528234A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002078607A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1301267C (zh) * | 2005-06-21 | 2007-02-21 | 中国人民解放军军事医学科学院附属医院 | Muc1粘蛋白的一个模拟表位肽及其编码dna与应用 |
| CN101678116A (zh) * | 2006-05-11 | 2010-03-24 | 根特大学 | 通过唾液酸粘附素靶向巨噬细胞 |
| CN112574283B (zh) * | 2020-12-07 | 2022-07-05 | 湖北文理学院 | 一种人muc1特异性结合多肽及其提取方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
-
2002
- 2002-04-02 AT AT02757916T patent/ATE376836T1/de not_active IP Right Cessation
- 2002-04-02 CA CA002443045A patent/CA2443045A1/en not_active Abandoned
- 2002-04-02 US US10/113,800 patent/US7285282B2/en not_active Expired - Fee Related
- 2002-04-02 KR KR10-2003-7012901A patent/KR20030092044A/ko not_active Withdrawn
- 2002-04-02 NZ NZ528234A patent/NZ528234A/en unknown
- 2002-04-02 EP EP02757916A patent/EP1372691B1/en not_active Expired - Lifetime
- 2002-04-02 JP JP2002576876A patent/JP4223813B2/ja not_active Expired - Fee Related
- 2002-04-02 WO PCT/US2002/010155 patent/WO2002078607A2/en not_active Ceased
- 2002-04-02 CN CNA028077784A patent/CN1525864A/zh active Pending
- 2002-04-02 DE DE60223232T patent/DE60223232T2/de not_active Expired - Fee Related
- 2002-04-02 BR BR0208771-5A patent/BR0208771A/pt not_active IP Right Cessation
-
2004
- 2004-08-04 US US10/910,612 patent/US20050095675A1/en not_active Abandoned
-
2005
- 2005-04-05 JP JP2005109271A patent/JP2005247861A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| NZ528234A (en) | 2006-01-27 |
| ATE376836T1 (de) | 2007-11-15 |
| JP2005247861A (ja) | 2005-09-15 |
| CA2443045A1 (en) | 2002-10-10 |
| US7285282B2 (en) | 2007-10-23 |
| EP1372691B1 (en) | 2007-10-31 |
| DE60223232D1 (de) | 2007-12-13 |
| CN1525864A (zh) | 2004-09-01 |
| US20050095675A1 (en) | 2005-05-05 |
| WO2002078607A2 (en) | 2002-10-10 |
| WO2002078607A3 (en) | 2003-03-27 |
| US20030166853A1 (en) | 2003-09-04 |
| KR20030092044A (ko) | 2003-12-03 |
| EP1372691A2 (en) | 2004-01-02 |
| EP1372691A4 (en) | 2005-11-09 |
| JP4223813B2 (ja) | 2009-02-12 |
| JP2004532018A (ja) | 2004-10-21 |
| DE60223232T2 (de) | 2008-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chandy et al. | Peptide blockers of Kv1. 3 channels in T cells as therapeutics for autoimmune disease | |
| US5696078A (en) | Methods of treating fungal infections using histatin-based peptides | |
| Dalum et al. | Breaking of B cell tolerance toward a highly conserved self protein | |
| MX9406552A (es) | Metodo, composiciones y dispositivos para la admi nistracion de polinucleotidos desnudos que codifi can peptidos biologicamente activos. | |
| ES2584430T3 (es) | Estrategias para prevenir y/o tratar las respuestas inmunitarias a los alofactores solubles | |
| KR102314231B1 (ko) | 전립선 암 치료용 조성물 | |
| BRPI0208183B8 (pt) | peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer | |
| CY1113379T1 (el) | Πεπτιδια κdr και εμβολια που τα περιλαμβανουν | |
| ES2373055T3 (es) | Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno. | |
| ES2112838T3 (es) | Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas. | |
| BRPI0010612B8 (pt) | vacinas | |
| BR0308101A (pt) | Vacinas de dna que codificam cea e um ligante de cd40 e seus métodos de uso | |
| BR0012919A (pt) | Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv | |
| ES2398492T3 (es) | Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1 | |
| JP3986481B2 (ja) | シャペロニン１０ | |
| ATE103297T1 (de) | Peptid, immunogene zusammensetzung und impfstoff oder medizinische zubereitung, eine methode zur immunisierung eines saeugetieres gegen lhrh und methode zur verbesserung von mea. | |
| ATE205219T1 (de) | Ein verbessertes peptid, immunogene zusammensetzung und impfstoff oder medizinische präparate, eine methode zur immunisierung von tieren gegen das hormon lhrh und analoge des lhrh-tendem-repeat-peptid und deren verwendung als impfstoff | |
| US20070116672A1 (en) | Treatment of rheumatic diseases | |
| TW434257B (en) | Proteins from mammalian liver and their use in oncology | |
| BR0016129A (pt) | Molécula de ácido nucléico, vetor recombinante, polipeptìdeo, racemase de aminoácido eucariótica, anticorpos, célula hospedeira, métodos para produzir polipeptìdeo, para detectar um parasita e uma proteìna eucariótica, para triar moléculas ativas, para detectar e quantificar a presença ou a ausência de uma sequência, para inibir uma proteìna eucariótica, para produzir uma racemase de aminoácido recombinante eucariótica e d-aminoácio e para prevenir ou inibir infecção, plasmìdeo, complexo imunológico, kit para detectar um parasita, fragmento de um polinucleotìdeo, proteìna eucariótica, processos para preparar uma proteìna eucariótica purificada, para detectar uma infecção e para infecção e para triar uma molécula, composição imunizadora, composição de vacina, qualquer modificação molecular do gene ou de um fragmento do gene, uso de qualquer modificação molecular ou bioquìmica da atividade enzimática da racemase, e, qualquer molécula ou composto | |
| BR0208771A (pt) | Peptìdeo ou poliptìdeo isolados e seus derivados, ácido nucléico codificando o mesmo, vacina copreendendo o mesmo, ácido nucléico codificando o mesmo, vetor compreendendo o referido ácido nucléico, célula hospedeira compreendendo o referido ácido nucléico, composição farmacêutica compreendendo o referido peptìdeo ou polipeptìdeo, método para tratamento ou prevençao de câncer utilizando a referida composição farmacêutica e método para induzir ou magnificar uma resposta imunológica utilizando a referida composição farmacêutica | |
| JP2008509072A (ja) | 改良型ワクチン用のポリペプチド‐アジュバント複合体 | |
| Ellerman et al. | Immunocontraceptive properties of recombinant sperm protein DE: implications for the development of novel contraceptives | |
| AU3390995A (en) | Novel implant and novel vector for the treatment of acquired diseases | |
| AR014884A1 (es) | Uso de un conjugado de angiotensina inmunogenico y composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A,6A E 7A ANUIDADES |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009. |